According to the American Cancer Society, prostate cancer is the most common type of cancer found in American men, other than skin cancer.
OncoSec to Present at Upcoming Investor and Scientific Conferences
OncoSec Medical is a biopharmaceutical company developing advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers and metastatic disease.
Industry Veteran Named CEO of Vigilant Biosciences
New “rinse and spit” screen for oral cancer could reduce disfigurement and save lives. Vigilant Biosciences, Inc., recently announced the appointment of David Barshis as Chief Executive Officer.
Immunotherapy Trains the Immune System to Attack Cancer Cells
Immunotherapy is the new black when it comes to treating Cancer, raising hope in conquering this age old illness.
Four Cancer Therapies to Watch
On June 1, more than 25,000 cancer specialists will come together at the 2012 American Society of Clinical Oncology Annual Meeting in Chicago. With ASCO hours away, we look at some small biotech companies making headway in cancer treatment.
OneMedRadio: NanoViricides CEO Discusses U.S. Patent
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for antiviral therapy.
This Week In Diagnostics
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
The Technology Corner: Disruptive Technology for Prostate Cancer
In this special series we present emerging technologies which hold the promise to significantly improve the prognosis of patients diagnosed with prostate cancer, and cancer in general.